Medicamen Biotech profit and loss

Latest FY26

Revenue: ₹198cr+21.7% on FY25
EBITDA: ₹19.6cr+41.3% on FY25
Net profit: ₹9.8cr+49.4% on FY25
EPS: ₹7.22+39.9% on FY25

₹ crore except per share

Tap a line for its trend	Last 12Mto Jun 2026	FY26Mar 2026	FY25Mar 2025	FY24Mar 2024	FY23Mar 2023	FY22 and earlierAlpha Plus

Expenses
	203	198	163	179	141	FY22 and earlierEvery year the company has filed comes with Alpha Plus.
	3.5	3.1	6.2	2.3	2.5
	206	201	169	182	143
	92.4	94.3	90.6	105	81.8
	7.8	7.4	−6.0	−12.1	−9.7
	35.9	34.7	31.9	30.1	20.4
	3.2	3.5	3.2	4.4	2.9
	7.2	7.2	7.1	7.1	6.4
	47.2	41.7	32.2	34.4	24.5
	194	189	159	169	126
	19.3	19.6	13.9	22.2	23.9
	12.1	12.4	6.8	15.1	17.5
Profit
	12.4	12.0	9.9	13.1	17.0
	12.4	12.0	9.9	13.1	17.0
	2.8	2.5	3.6	4.2	3.7
	−0.4	−0.4	−0.3	−0.6	−1.4
	2.4	2.2	3.3	3.6	2.3
	10.0	9.8	6.6	9.5	14.7
	10.0	9.8	6.6	9.5	14.7
	10.0	9.8	6.6	9.5	14.7
	10.8	9.6	7.1	10.9	14.8
	−0.8	0.2	−0.6	−1.4	−0.1
Per share
	₹7.41	₹7.22	₹5.16	₹7.50	₹11.82
	₹7.41	₹7.22	₹5.16	₹7.50	₹11.82
Other comprehensive income — detail
	—	—	—	10.9	14.8
	—	—	—	−1.4	−0.1
Per share — as-filed variants
	₹7.41	₹7.22	₹5.16	₹7.50	₹11.82
	₹7.41	₹7.22	₹5.16	₹7.50	₹11.82
Derived — gross profit (revenue − materials − purchases − Δ inventories)
	102	96.0	77.9	86.7	68.8
	50.6%	48.5%	47.9%	48.4%	48.8%
Adjusted (ex-exceptional items) — derived
	12.4	12.0	9.9	13.1	17.0
	10.0	9.8	6.6	9.5	14.7
	₹7.41	₹7.22	₹5.16	₹7.50	₹11.82

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

MEDICAMEQ₹254.25

Medicamen Biotech Limited

· Pharma & Health

Annual Quarterly₹ CrorePeersMEDICO AAREYDRUGS NECLIFE HALEOSLABS ALBERTDAVD NATCAPSUQ VALIANTLAB BALPHARMAMcap ₹345 Cr

View

In ₹ Crore except Per Share 12 Months Ending	FY23 31/03/2023	FY24 31/03/2024	FY25 31/03/2025	FY26 31/03/2026	Last 12M 30/06/2026
Revenue from Operations	140.9	179.3	162.5	197.8	202.6
Other Income	2.5	2.3	6.2	3.1	3.5
Total Income	143.3	181.6	168.8	200.9	206.1
Expenses
+ Cost of Materials Consumed	81.8	104.7	90.6	94.3	92.4
+ Changes in Inventories	-9.7	-12.1	-6.0	7.4	7.8
+ Employee Benefit Expense	20.4	30.1	31.9	34.7	35.9
+ Finance Costs	2.9	4.4	3.2	3.5	3.2
+ Depreciation & Amortisation	6.4	7.1	7.1	7.2	7.2
+ Other Expenses	24.5	34.4	32.2	41.7	47.2
Total Expenses	126.3	168.6	158.9	188.9	193.7
EBITDA	23.9	22.2	13.9	19.6	19.3
EBIT	17.5	15.1	6.8	12.4	12.1
Profit
PBT before Exceptional Items	17.0	13.1	9.9	12.0	12.4
Pretax Income	17.0	13.1	9.9	12.0	12.4
+ Current Tax	3.7	4.2	3.6	2.5	2.8
+ Deferred Tax	-1.4	-0.6	-0.3	-0.4	-0.4
Tax Expense	2.3	3.6	3.3	2.2	2.4
Net Income	14.7	9.5	6.6	9.8	10.0
+ Net Income — Continuing Ops	14.7	9.5	6.6	9.8	10.0
Total Comprehensive Income	14.7	9.5	6.6	9.8	10.0
Net Income to Common	14.8	10.9	7.1	9.6	10.8
Minority Interest	-0.1	-1.4	-0.6	0.2	-0.8
Per Share
Basic EPS	11.82	7.50	5.16	7.22	7.41
Diluted EPS	11.82	7.50	5.16	7.22	7.41
Other Comprehensive Income — detail
Comprehensive Income — Owners of Parent	14.8	10.9	—	—	—
Comprehensive Income — Non-controlling Interests	-0.1	-1.4	—	—	—
Per Share — as-filed variants
Basic EPS — Continuing Operations	11.82	7.50	5.16	7.22	7.41
Diluted EPS — Continuing Operations	11.82	7.50	5.16	7.22	7.41
Derived — Gross Profit (Revenue − Materials − Purchases − Δ Inventories)
Gross Profit	68.8	86.7	77.9	96.0	102.4
Gross Margin %	48.82	48.36	47.94	48.54	50.56
Adjusted (ex-Exceptional Items) — derived
Pretax Income (Adjusted, as filed)	17.0	13.1	9.9	12.0	12.4
Net Income Adj (tax-effected)	14.7	9.5	6.6	9.8	10.0
EPS Adj	11.82	7.50	5.16	7.22	7.41
Other Filed Concepts — mapped but not yet placed in the schedule
Face Value	10.00	10.00	10.00	10.00	10.00
Paid Up Equity Capital	12.7	12.7	12.7	13.6	13.6

As filed, sign as filed — read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown, so depth follows the filer: pre-Ind-AS, insurance and NBFC blocks stay hidden unless they were actually reported. Alternate tags for the same idea (e.g. two spellings of a deferred-tax element) are kept as separate lines rather than merged, because merging them would be a guess. Ratios, per-share figures and counts render as raw numbers, not ₹ Crore. No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.